Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

al achieved the primary endpoint of median Time to Last Unformed Stool (TLUS). Median TLUS for patients treated with prulifloxacin was 32.8 hours which was statistically significant compared to the TLUS for placebo with a p-value of less than 0.0001. Prulifloxacin was generally well tolerated and had a similar safety profile compared to placebo. This is the second of two pivotal Phase 3 clinical studies which will be used to support an NDA submission with the U.S. Food and Drug Administration.
  • Raised $32.9 million in gross proceeds through the sale of 3.3 million shares and warrants to purchase 91,533 shares in a registered direct offering in March 2009.
  • Appointed Francois-Xavier Frapaise, M.D., as Senior Vice President and Chief Scientific Officer and Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations at Cephalon, Inc. (Nasdaq: CEPH), to the company's Board of Directors.
  • Published in vitro data highlighting the antibacterial activity of prulifloxacin in the peer-reviewed journal Antimicrobial Agents and Chemotherapy.

  • About Optimer Pharmaceuticals

    Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
    3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
    4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
    5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
    6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
    7. Idenix Pharmaceuticals Reports First Quarter Financial Results
    8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
    9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
    10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
    11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/14/2014)... July 14, 2014 Cloud Pharmaceuticals, Inc., ... and development, announced today the expansion of its ... been granted supercomputing time at Argonne National Laboratory ... Through a discretionary allocation of 1 ... (ALCF), researchers at Cloud Pharmaceuticals will use Mira, ...
    (Date:7/14/2014)... Throughout this past June 100s of ... space, representing 38 countries globally, registered for Xtalks ... Participation in Clinical Trials. Attract. Engage. Retain.” , ... R&D expert, Ken Getz, of Tufts CSDD, who ... through Patient Centricity. , Throughout this complimentary six-part ...
    (Date:7/14/2014)... 2014 Minerva Neurosciences (NASDAQ: NERV ... to treat neuropsychiatric diseases and disorders, today announced that ... president of finance and chief accounting officer, effective June ... executive with more than 20 years of experience in ... companies. His background includes the management of compliance and ...
    (Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
    Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
    ... ... Hermes Biosciences and partnership with sanofi-aventis , ... Cambridge, MA (PRWEB) April 7, 2010 -- Merrimack Pharmaceuticals, Inc., ... for cancer and inflammation, today announced that William Sullivan has been promoted to Vice ...
    ... have found a way to turn a precision measurement device ... researchers adapted a device known as an optical frequency comb ... data operations that will be vital for future quantum computers. ... Review Letters and is described in a Viewpoint article ...
    ... ... to build and sell "Flexible Fuel" cars, as would be required by ... the impact of the stricter fuel efficiency standards announced today by President ... President,s announcement, advocates of energy independence challenged the President to show his ...
    Cached Biology Technology:Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance 2Challenge President to Adopt Energy Measure with Double the Impact of Improved Auto Fuel Efficiency Standards at Fraction of the Cost 2
    (Date:7/14/2014)... news release is available in German . ... segmental patterns that manifest themselves during development. One classical ... precursors of the backbone, a process that has been ... embryo the "segmentation clock". Until now, this patterning ... time scale of genetic oscillations that periodically trigger new ...
    (Date:7/14/2014)... July 14, 2014 MedNet Solutions ... in clinical study management systems, is pleased to ... equity firm focused on software-as-a-service (SaaS) and Internet-based ... MedNet Solutions.  This funding, representing the first major ... instrumental in supporting the ongoing growth and development ...
    (Date:7/14/2014)... 14, 2014 Research and Markets has ... 2014: Applications for Microfluidic Technologies" report to their offering. ... testing based on microfluidic technology is expected to grow sharply, ... CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, ... etc.) have realized the potential of rapid molecular diagnostic testing. ...
    Breaking Biology News(10 mins):Timing is not only ticking 2Timing is not only ticking 3Arrowroot Capital Invests $4 Million In MedNet Solutions 2Arrowroot Capital Invests $4 Million In MedNet Solutions 3Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 2Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 3
    ... in decks, utility poles and fences will likely leach ... groundwater, according to two research papers published online Wednesday. ... of Florida and Florida International University examined arsenic leaching ... real deck as well as from simulated landfills. , ...
    ... using MRI to detect magnetic probes of tiny iron ... time has successfully tracked immune-stimulating cells implanted into cancer ... the eight patients, MRI revealed that the implanted cells ... for treatment," says Jeff Bulte, Ph.D., an associate professor ...
    ... chicken when she crossed the road is less important that what ... , Organic arsenic is fed to poultry to prevent bacterial infections ... up by the tissue and the majority of it is excreted ... urine from under poultry houses -- is rich in nitrogen and ...
    Cached Biology News:Researchers: Treated wood poses long-term threat 2Researchers: Treated wood poses long-term threat 3Magnetic probe successfully tracks implanted cells in cancer patients 2Magnetic probe successfully tracks implanted cells in cancer patients 3Geoscientists follow arsenic from chicken feed to streambeds 2
    Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
    WTAP Antibody...
    Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
    ... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
    Biology Products: